Patients with type 2 diabetes (T2D) and cardiovascular disease (CVD) had fewer major CV events when given the GLP-1* receptor agonist albiglutide compared with placebo, adding to the CV benefit profile of GLP-1 receptor agonists, according to results of the Harmony Outcomes** trial presented at EASD 2018.
Hybrid closed-loop insulin therapy in patients with suboptimally controlled type 1 diabetes (T1D) helps to keep their sugar levels within range, a 12-week multicentre, multinational trial has shown, supporting the utility of closed-loop technology in clinical practice.
The GLP-1* receptor agonist lixisenatide may slow the progression of micro- and macroalbuminuria in patients with type 2 diabetes (T2D) and acute coronary syndrome, based on an exploratory analysis of the ELIXA** trial presented at EASD 2018.
Treatment with twincretin, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-1 receptor agonist combined into a single drug (LY3298176), not only reduced blood glucose in patients with type 2 diabetes (T2D) – it came with an added benefit of weight loss, with no increase in hypoglycaemia in a phase IIb trial.
Treatment with the DPP-4* inhibitor linagliptin in addition to the standard of care has no impact on heart failure, cardiovascular (CV), or renal events compared with standard of care alone in patients with type 2 diabetes (T2D) who had a very high risk of CV events and/or kidney disease progression, according to the CARMELINA** postmarketing outcomes study, thus providing reassurance on the CV safety of at least one member of the drug class.
Long-term therapy with testosterone undecanoate (TU) in hypogonadal men with type 2 diabetes (T2D) may improve glycaemic control and reverse disease progression, as well as induce significant weight loss, according to a study presented at EASD 2018.
Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
Multiple intralesional injections with purified protein derivative (PPD) leads to faster clearance of common warts compared with a single injection, although the latter is better tolerated, as shown in the results of an open‐label, superiority trial.
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.